TICKERNERD
Menu
STOKSTOKHealthcare · Biotechnology

STOK Stock Forecast: Stoke Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 8 Oct 2026
$24
−1.40% on the day

The 14 Wall Street analysts covering Stoke Therapeutics, Inc. hold a median 12-month price target of $44 — +83.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 49 of 100 as at 8 Oct 2026 — in the lower half.

Market cap
$1.6B
Ticker Nerd rank
49 / 100
Median analyst target
$44
Analysts covering
14
Revenue$9.3M−32.5% y/y
Operating income−$65.4M
Net income−$61.6M
Free cash flow−$58.6M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−7.9%
1M
−20.3%
YTD
−24.5%
1Y
−21.5%
From 52W high
−37.5%
From 52W low
+7.1%
$22
$38
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

STOK stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Stoke Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 8 Oct 2026
49 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
73
Momentum
72
Quality
66
Volatility
65
Value
61
Issuance
43
Revisions
40
Size
39
Growth
18

Accruals (73): Reported profit is backed by cash, and the company is not expanding recklessly.

Growth (18): Sales and profits are flat, shrinking, or growing more slowly than they were.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

STOK stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on STOK, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$20$30$40$50$60Jan 26Apr 26Jul 26Oct 26STOKHigh $60Median $44Low $35

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says14 analysts
14 Buy0 Hold0 Sell
Low $35Median $44High $60

The green dot is the last close — the median target sits +83.7% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
21 Aug 2026JP MorganReinstatesOverweight$40
4 Aug 2026Canaccord GenuityMaintainsBuy$60 → $58
4 Aug 2026Canaccord GenuityMaintainsBuy—
4 Aug 2026Chardan CapitalMaintainsBuy—
4 Aug 2026Chardan CapitalMaintainsBuy$35
4 Aug 2026GuggenheimReiteratesBuy—
4 Aug 2026GuggenheimReiteratesBuy$60
4 Aug 2026WedbushMaintainsOutperform—
4 Aug 2026WedbushMaintainsOutperform$38 → $40
13 July 2026Goldman SachsInitiatesBuy—
13 July 2026Goldman SachsInitiatesBuy$44
11 May 2026BTIGReiteratesBuy—
20 Mar 2026Canaccord GenuityMaintainsBuy—
19 Mar 2026BTIGReiteratesBuy—
18 Mar 2026Chardan CapitalMaintainsBuy—
18 Mar 2026WedbushMaintainsOutperform—
17 Mar 2026NeedhamMaintainsBuy—
17 Mar 2026WedbushMaintainsOutperform—
24 Feb 2026Wolfe ResearchInitiatesOutperform—
12 Jan 2026WedbushMaintainsOutperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. STOK appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

STOK vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 8 Oct 2026, Stoke Therapeutics, Inc. returned −21.5% against +16.2% for the S&P 500, dividends included.

STOK vs S&P 500, last 12 monthsTotal return, rebased to 100
708090100110120130Jan 26Apr 26Jul 26Oct 26STOKS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

STOK analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
4
Fundamentals

Stoke Therapeutics, Inc. (STOK) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
48.8×

Cheaper than 15% of US stocks

Price / sales
57.0×

Cheaper than 5% of US stocks

Price / book
4.4×

Cheaper than 23% of US stocks

EV / EBITDA
−5.8×

Cheaper than 81% of US stocks

Growth & margins
Revenue growth (YoY)
−32.5%

Higher than 8% of US stocks

Earnings growth (YoY)
−32.5%

Higher than 15% of US stocks

Gross margin
—
Operating margin
−701.7%

Higher than 6% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−61.1%

Higher than 19% of US stocks

Return on assets
−35.9%

Higher than 12% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Stoke Therapeutics, Inc. (STOK) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Stoke Therapeutics, Inc. has a market value of $1.6B and an enterprise value of $1.3B.

  • Revenue in the twelve months to 30 June 2026: $27.6M. The latest quarter shrank 32.5% year on year.

  • Net income over the same four quarters: −$207.9M, a −753.6% net margin.

  • Free cash flow in the twelve months to 30 June 2026: −$180.7M.

  • Shares outstanding: 62.4M.

  • Trailing P/E: 48.8×; forward P/E: −6.9× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Stoke Therapeutics, Inc. employs 170 people — $162K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 7 Oct 2026

Data provided by Twelve Data

Peers

STOK vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
STOKStoke Therapeutics, Inc.$1.6B
49
RAREUltragenyx Pharmaceutical, Inc.$1.5B
43
SNDXSyndax Pharmaceuticals, Inc.$1.5B
59
ABSIAbsci Corp.$1.5B
35
KRSAKorsana Biosciences, Inc.$1.5B
38
QUREUniQure NV$1.5B
50
COAGHemab Therapeutics Holdings, Inc.$1.4B
1

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Stoke Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest STOK news & analysis

Stoke Therapeutics Announces Presentations of STK-002, an Investigational Medicine for the Treatment of Autosomal Dominant Optic Atrophy (ADOA), at the American Academy of Ophthalmology (AAO) 2026 Annual Meeting

Business Wire · 6 Oct 2026positive

Stoke Therapeutics announced two presentations of STK-002 data at the AAO 2026 Annual Meeting, scheduled for October 9–12 in New Orleans. STK-002 is an investigational medicine designed to increase OPA1 to target the underlying cause of autosomal dominant optic atrophy (ADOA).

Why it matters — The presentations will provide an opportunity to share data on Stoke’s investigational STK-002 program for ADOA.

Stoke Therapeutics Announces Completion of Successful Meeting with the FDA to Align on Planned U.S. NDA for Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome

Business Wire · 5 Oct 2026positive

Stoke Therapeutics announced the completion of a successful meeting with the FDA to align on key aspects of the planned U.S. New Drug Application for zorevunersen, its lead investigational medicine for the treatment of Dravet syndrome. Zorevunersen is being developed as a potential first-in-class, disease-modifying treatment.

Why it matters — STOK watchers would care because successful alignment with the FDA on the NDA plan advances zorevunersen's regulatory progress toward a potential U.S. submission.

Stoke Therapeutics Appoints Bo Cumbo to its Board of Directors, Enhancing Commercial Expertise as the Company Advances Zorevunersen Development Toward Potential FDA Approval and Commercialization

Business Wire · 23 Sept 2026positive

Stoke Therapeutics announced the appointment of Bo Cumbo to its Board of Directors, concurrent with the retirement of Edward Kaye, M.D. The company noted Cumbo's appointment enhances commercial expertise as it advances zorevunersen development toward potential FDA approval and commercialization.

Why it matters — A STOK watcher would care because the board addition brings commercial expertise relevant to the potential regulatory approval and commercialization of zorevunersen for Dravet syndrome.

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Business Wire · 16 Sept 2026neutral

Stoke Therapeutics announced that, effective September 15, 2026, it granted stock options to purchase an aggregate of 53,175 shares of common stock as inducement grants under Nasdaq Listing Rule 5635(c)(4). The company is developing zorevunersen as a potential treatment for Dravet syndrome.

Why it matters — STOK watchers would care because the inducement grants signal new hires or retention of key personnel, a routine corporate action that reflects the company's ongoing operations.

Stoke Therapeutics to Present at the Cantor Global Healthcare Conference

Business Wire · 2 Sept 2026neutral

Stoke Therapeutics announced that Chief Executive Officer Ian F. Smith and Chief Patient Officer Jason Hoitt will present at the Cantor Global Healthcare Conference. The company's lead investigational medicine, zorevunersen, is in development as a potential first-in-class disease-modifying treatment for Dravet syndrome.

Why it matters — STOK watchers would care because the presentation offers exposure and an opportunity for the company to discuss its lead investigational Dravet syndrome candidate, zorevunersen, with the investment community.

FAQ

Frequently asked questions about STOK stock

What is the STOK stock price forecast for 2026-2027?

The 14 Wall Street analysts covering Stoke Therapeutics, Inc. have a median 12-month price target of $44, with estimates ranging from $35 to $60. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is STOK stock a buy right now?

Of the 14 analysts covering Stoke Therapeutics, Inc., 14 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Stoke Therapeutics, Inc. 49 out of 100 across roughly 4,600 US stocks as at 8 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank STOK?

As at 8 Oct 2026, Stoke Therapeutics, Inc. ranks 49 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (73 of 100).

Will STOK stock go up?

No one can know that. What the data says: the median 12-month target from 14 analysts implies +83.7% from the last close, and Ticker Nerd's factor model ranks Stoke Therapeutics, Inc. 49 out of 100 as at 8 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the STOK stock forecast for 2030?

No analyst covering Stoke Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for STOK are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $35 to $60 over the next 12 months.

How has STOK stock performed over the past year?

Stoke Therapeutics, Inc. returned -21.5% over the 12 months to 8 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Stoke Therapeutics, Inc. do?

Stoke Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing RNA-based medicines for severe genetic diseases.

What is the latest news on STOK?

The most recent item we track (Business Wire, 6 Oct 2026): "Stoke Therapeutics Announces Presentations of STK-002, an Investigational Medicine for the Treatment of Autosomal Dominant Optic Atrophy (ADOA), at the American Academy of Ophthalmology (AAO) 2026 Annual Meeting". Stoke Therapeutics announced two presentations of STK-002 data at the AAO 2026 Annual Meeting, scheduled for October 9–12 in New Orleans. STK-002 is an investigational medicine designed to increase OPA1 to target the underlying cause of autosomal dominant optic atrophy (ADOA).

Company

About Stoke Therapeutics, Inc.

Stoke Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing RNA-based medicines for severe genetic diseases. Its programs are designed to upregulate protein expression and address the underlying cause of disorders linked to insufficient protein production. The company’s portfolio centers on precision therapies for rare neuromuscular, neurological, and other haploinsufficiency-related conditions, with a strong emphasis on antisense oligonucleotide approaches and targeted gene output modulation. Stoke Therapeutics operates in the genetic medicines and rare disease markets, where its research platform supports the discovery and development of treatments intended to restore healthier levels of naturally occurring proteins. Headquartered in Bedford, Massachusetts, Stoke Therapeutics plays a specialized role in advancing novel therapeutic approaches for patients with complex inherited diseases.

CEO Mr. Ian F. Smith A.C.A., C.P.A. · 170 employees · United States · https://www.stoketherapeutics.com